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Inflammatory/immune cytokines induce expressionof endothelial cell surface struc-
tures that bind leukocytes. Endothelial-leukocyte adhesion molecule 1 (ELAM-1)
(1, 2) primarily supports adhesion ofpolymorphonuclear leukocytes (PMN). Inter-
cellular adhesion molecule 1 (ICAM-1) (3, 4) contributes to the adhesion ofPMN,
monocytes, and lymphocytes through interaction with leukocyte cell surface mole-
cules of the CD11/CD18 complex (5-8). mAbs directed against CDll/CD18 mole-
cules or ICAM-1 only partially inhibit lymphocyte or monocyte binding to activated
endothelium (6, 7), suggesting the presence of additional adhesive mechanisms in
inflamed endothelium (6).
A novel, cytokine-inducible endothelial cell surface glycoprotein of 110 kD, termed
inducible cell adhesion molecule 110 (INCAM-110), was recently identified as a medi-
ator of melanoma cell-endothelial adhesion (9, 10). We now report that INCAM-
110 is involved in the adhesion of lymphocytes, monocytes, and certain leukocyte
cell lines to endothelium in vitro, and is upregulated in inflammatory reactions in vivo.





Human umbilical vein endothelial cells(HEC) were grown in microtiter wells
(Costar, Cambridge, MA) (11). Ramos (human Burkitt's lymphoma), CCRFCEM (human
T cell lymphoma; American Type Culture Collection, Rockville, MD), and an EBV
transformed B lymphoblastoid cell line (IB-4; gift of M. Kurilla, Boston, MA) were grown
in RPMI 1640 medium with 10% FCS (Gibco Laboratories, Grand Island, NY). Human
dermal fibroblasts (AlF21) were maintained in M199 with 15% FCS.
mAbs.
￿
mAbs El/6 (IgGl) and H18/7 (IgG2a) recognize INCAM-110 (10) and ELAM-1
(1), respectively. mAb E1/7 (IgG2a), raised against TNF-activated HEC, recognizes ICAM-1,
as demonstrated by immunoprecipitation and gel electrophoresis, and by immunobinding
to COS cells transfected with a cDNA encoding ICAM-1 (provided by B. Seed, Boston, MA).
mAbs E1/6 and El/7 were utilized as pooled hybridoma culture supernatants (RPMI 1640
with 10% horse serum) with maximal HEC surface binding and adhesion blocking activity
(as determined by titration studies). mAbs RRl/1 (IgGI, anti-ICAM-1), TS1/22 (IgGI, anti-
CD11a), and TSl/18 (IgG1, anti-CD18)were provided by T. Springer, Boston, MA. Anti-leu-
M3 (monocyte marker) was obtained from Becton Dickinson & Co., Mountain View, CA.
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PMN were obtained from peripheral blood as described (11).
Mononuclear cell fractions were washed in HBSS with 0.1% BSA (Sigma Chemical Co., St.
Louis, MO) to remove platelets, and resuspended into RPMI with 0.1% BSA. Monocytes
were isolated by two rounds of adhesion (30-60 min, 370C) to gelatin-coated tissue culture
plastic (Costar) that had been exposed to autologous platelet-free plasma for 30 min at 37°C.
Adherent cells were collected with EDTA (2-4 mM, 15 min, 370C). Lymphocyte- and
monocyte-enriched fractions were also prepared by countercurrent flow elutriation (11).
Adhesion Assays.
￿
Leukocytes were labeled with 2', 7'-bis-(-2-carboxyethyl)-5 (and -6) car-
boxyfluorescein, acetoxymethyl ester(BCECFAM ; Molecular Probes Inc., Eugene, OR) (2-
5 mM, diluted from 1-M stock in DMSO; 20 min at 37'C) and resuspended in RPMI with
10% FCS. In some experiments, leukocytes were treated (20-30 min, 4°C) with heat-aggregated
rabbit Ig (Pel-Freeze Biologicals, Rogers, AR; 10-20 mg/ml final concentration) to block poten-
tial Fc receptor interactions (1). HEC were incubated with mAbs (100 til/well, culture super-
natant or dilutions ofascites protein at 10 Wg/ml) for 30 min at 37'C before addition of0.5-2 x
10' leukocytes per well. mAbs were not routinely removed. After 30 min at 25'C, assay plates
were inverted and centrifuged (1); the number of bound leukocytes was determined using
an automated fluorescence concentration analyzer (Pandex Laboratories, Inc., Mundelein,
IL). In certain experiments, leukocytes were treated with anti-CD11/CD18 mAbs (dilution
of ascites, 1 :200 or 1 :500) at 4oC for 20-30 min before assay.
Flow Cytometry, RIA, and Immunostaining.
￿
For flow cytometry, 5 x 105 cells were exposed
to primary mAbs (4oC, 30 min) followed by fluorescein-conjugated goat anti-mouse Ig
(Boehringer Mannheim Biochemicals, Indianapolis, IN) (1 :50 dilution in HBSS with 0.1%
BSA; 4oC, 20 min), and fixed in I% paraformaldehyde in PBS. Cell surface RIAs were per-
formed using "sI sheep anti-mouse Ig (New England Nuclear, Cambridge, MA) (1). For
immunoperoxidase studies, cryostat sections of human tissues were exposed to mAbs (16 h
at 4oC) and developed using aminoethylcarbazole or diaminobenzidine as chromagens.
Results and Discussion
Expression ofINCAM-110 In Vitro.
￿
Fewer than 10% of unstimulated HEC bound
mAb El/6 by flow cytometric analysis, consistentwith the low level expression previ-
ously observed by cell surface RIA (10). mAb E1/6 bound to >80% of IL-1- or TNF
treated HEC, with an increase in mean fluorescence intensity of N20-fold. mAb El/6
did not bind to blood mononuclear cells (lymphocytes and monocytes), PMN, or
human dermal fibroblasts (AlF21 cells; RIA).
INCAM-110 and ICAM-1 Independently Mediate Lymphocyte Adhesion to Endothelial
Monolayers. Exposure of HEC to IL-1 (5 U/ml, 6-8 h) increased the adhesion of
PBL by 4.8 t 0.9 times (mean t SEM; five experiments). Anti-INCAM-110 mAb
El/6 inhibited adhesion of PBL to IL-1-activated HEC by 41 t 5% (five experi-
ments) (Fig. 1) . Treatment ofPBL with mAb El/6 (30 min, 4oC) followed by washing
had no effect (data not shown). Anti-ICAM-1 mAb E1/7 also inhibited PBL adhe-
sion to HEC, but to a lesser degree (12 t 3% ; four experiments) (6). mAbs El/6
and El/7 in combination blocked PBL adhesion by 68 t 3%, while two irrelevant,
isotype-matched mAbs (which bind to both control and cytokine-activated HEC)
had no effect. Similar results were observed using anti-ICAM-1 mAb RRl/l (data
not shown) .
mAb El/6 blocked the adhesion of Ramos cells (60 t 7 % ; four experiments) (Fig.
1), whereas anti-ICAM-1 mAb E1/7 had no effect (-1 t 5% inhibition). In con-
trast, adhesion of an EBVtransformed B lymphoblastoid cell line (IB-4) was not
substantially blocked by mAb El/6 alone (<10%), but was inhibited by mAb E1/7















Effects ofanti-ICAM-1 and anti-INCAM-110 mAbs on lymphocyte adhesion HEC.
Unstimulated (C) and IL-1-stimulated (6 h; 5 U/ml, rIL-10; gift of Biogen, Cambridge, MA)
HEC monolayers were treated with no mAb (open bars), anti-ICAM-1 mAb El/7 (hatched bars),
or anti-INCAM-110 mAb El/6 (solid bars) culture supernatants for 30 min before addition oflym-
phoid cells. Lymphocytes (<2% leu-M3 reactive) were isolated by flow elutriation. Bars repre-
sent mean t SD of quadruplicate microtiter wells.
ofmAbsEl/6 and E1/7 (55 t 6%)thanwithEl/7 alone, suggestinga role forINCAM-
110 in IB-4 adhesion. CEM cells (T lymphoblastic lymphoma) were more affected
by mAb El/6 than by mAb E1/7 (Fig. 1). These data suggest that INCAM-110 and
ICAM-1 function independently to mediate lymphocyte adhesion.
INCAM-110 Mediates Lymphocyte Adhesion by a CD111CD18-independent Mecha-
nism. mAb TSI/22 (anti-CD11a) inhibited the adhesion of PBL to IL-1-activated
HEC by 30 t 6% (mean f SEM; fourexperiments) (Table I). mAbE1/6 incombi-
nation with mAb TSl/22 resulted in greater inhibition ofPBL adhesion (69 t 9%
decrease; four experiments) than either mAb alone. Similarly, the combination of
TABLE I
Effects of mAbs Directed Against CD11a, ICAM-1, and INCAM-110
on Lymphocyte and Monocyte Adhesion to IL-1-activated HEC
Blood lymphocytes (<2% leu-M3 reactive) and monocytes (90% leu-M3 reactive) were in-
cubated in media without mAb, or with mAb TS1/22 (1:200 or 1 :500 dilution of ascites prepa-
ration) for 20 min at 4°C . The leukocyte preparations were warmed to 37°C, added to
IL-1-activated HEC monolayers (which had been incubated without mAb, with anti-ICAM-1
mAb El/7, or with anti-INCAM-110 mAb E1/6; 30 min, 37°C), and a 30-min adhesion
assay was performed. Adhesion of lymphocytes and monocytes to unstimulated HEC was
248 t 46 and 357 t 20 cells/mm2, respectively. Data presented are mean t SD of qua-
druplicate microtiter wells.
" p < 0.001 compared with TSI/22 treatment alone, student's t test.
p < 0.01 compared with TSI/22 treatment alone.
Leukocytes bound per mm2
Lymphocytes Monocytes
HEC treatment No mAb TSI/22 No mAb TSI/22
No mAb 962 t 88 808 t 41 895 t 52 688 t 9
mAb E1/7 (ICAM-1) 816 t 65 726 t 67 699 t 28 682 t 46





mAb E1/6 and an antibody directed against CD18 (mAb TS1/18)inhibitedPBLadhe-
sion by 78 t 1% (two experiments). These data suggest that LFA-1 and INCAM-
110 function independently in PBL adhesion. LFA-1 and ICAM-1 interact directly
as a receptor/ligand pair (5). Combinations of mAb directed against ICAM-1 (El/7,
RR1/1) and LFA-1 (TSl/22) were no more effective in blocking adhesion (30 t 10%
inhibition; three experiments) than anti-LFA-1 alone. In addition, CD11a was not
detected on Ramos cells (flow cytometric analysis; two experiments), which bind
to activated HEC by an INCAM-110-dependent mechanism (Fig. 1). Finally, lym-
phoblasts deficient in CD11/CD18 (prepared by IL-2 stimulation of PBLfrom apa-
tient with leukocyte adhesion deficiency; gift of D. Anderson, Houston, TX) were
partially inhibited by mAb El/6 (single experiment), but not by mAb E1/7 . Taken
together, thesedata strongly suggest that INCAM-110bindingoflymphoid cells does
not require CD1I/CD18.
The Role ofINCAM-110 in MonocyteAdhesion.
￿
Anti-INCAM-110 mAb E1/6 blocked
the adhesion of U937 cells to TNFactivated HEC by 49 t 11°Jo (two experiments),
suggesting that monocytic cells recognize INCAM-110. Using unstimulated HEC
monolayers, which express INCAM-110 (10) and ICAM-1 (3, 4) at low levels, mAbs
El/6 and El/7 reduced the binding of isolated blood monocytes by 27 t 7% and
43 t 7%, respectively. On cytokine-activated HEC, mAb El/6 alonehad little effect
on the adhesion ofmonocytes(8 t 2% decrease; 10 experiments); mAb E1/7 blocked
adhesion by 17 t 3% (nine experiments). Combinations of mAbs El/6 and E1/7
were more effective than either reagent alone (43 t 5% inhibition; p <0.001), fur-
ther suggesting a role for INCAM-110 in monocyte adhesion. Similar results were
observed with combinations of mAbs E1/6 and anti-CDlla (Table 1).
PMNadhesion to IL-1-activated HEC exhibitedlittle or no dependence on INCAM-
110. mAb El/6 alone did not block PMN adhesion (1 t 6% inhibition; four experi-
ments), nor did it further reduce the adhesion observed in the presence of blocking
mAb against ICAM-1 or CD11/CD18 (data not shown).
In Situ Expression ofINCAM-110 in Lymphoid Tissues andSitesofInflammation.
￿
Anti-
INCAM-110 mAb E1/6 did not bind to endothelium of normal human skin (Fig.
2 A) (10), but strongly reacted with small vessels(predominantly venules) associated
with florid perivascular inflammatory infiltration in adelayedhypersensitivity reac-
tion to tuberculin (72h) (Fig. 2B). Similarly, mAb El/6 boundto vascular endothelium
in acutaneous insect bite reaction. mAb El/6 bound focally to venular endothelium
in peripheral lymphnode and tonsil (typically 5-20% ofvessels), but did not to mark
high endothelial venules selectively. mAb El/6 also bound to cells within lymphoid
follicles (Fig. 2 C) and certain interfollicular cells (Fig. 2 D) having the appearance
of follicular dendritic and interdigitating dendritic cells, respectively. INCAM-110
on dendritic cells could influence lymphocyte localization or antigen presentation,
which may involve direct adhesive interactions (12).
Increasing evidence suggests that activated vascular endothelium can affect the
pattern and makeup of inflammatory cell infiltrates through expression of specific
adhesion molecules (13). ELAM-1 appears to function primarily in the adhesion of
PMN (1, 2), while ICAM-1 appears to mediate adhesion of most leukocyte types
(6-8). The present studies indicate that INCAM-110 supports the adhesion of lym-
phocytes and monocytes, but not PMN. Expression of INCAM-110 on activated en-RICE ET AL .
￿
BRIEF DEFINITIVE REPORT 1373
FIGURE 2.
￿
Photomicrographs offrozen sections ofhuman tissues stained with an immunoperox-
idase technique using mAb El/6 . Normal human skin (A) demonstrated little or no binding of
mAb El/6, whereas the endothelial lining of vessels in a delayed-type hypersensitivity reaction
(tuberculin) induced in the same patient (B) was strongly positive. In human tonsil (C), mAb
El/6 reacted with vascular endothelium in a minority of small vessels . mAb El/6 also bound
extensively to lymphoid follicles (C), primarily decorating cells ofdendriticmorphology . Interfol-
licular cells with dendriticmorphology were also marked (D) . No significant reactivity wasnoted
with control mAb K16/16 (IgGl) .
dothelium in vitro is more sustained than that ofELAM-1, suggesting that it may
act in concert with ICAM-1 in the development of chronic inflammatory processes .
Summary
Inducible cell adhesion molecule 110 (INCAM-110) is a 110-kD glycoprotein ex-
pressed on cytokine-activated humanvascular endothelial cells .mAbblocking studies
indicate thatINCAM-110and intercellular adhesion molecule 1 (ICAM-1) indepen-
dently support the adhesion of lymphocytes to activated human umbilical vein en-
dothelial cell monolayers. Anti-CDlla/CD18 antibodies withanti-INCAM-110 mAb
E1/6 produce greater inhibition of lymphocyte adhesion than either reagent alone,
suggesting that INCAM-110 and LFA-1 are not an obligate receptor-ligand pair. Blood
monocytes, but not polymorphonuclear leukocytes, also appear to bind endothelial
INCAM-110 . Endothelial expression ofINCAM-110 is upregulated at sites of inflam-
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